Drug Development

Pivotal phase III trial of drug for Huntington disease commences

Published in Pain and Central Nervous System Week, January 23rd, 2006

Amarin Corp. plc (AMRN) has announced the start of the European phase III clinical trial of Miraxion in Huntington disease.

The U.S. phase III clinical trial of Miraxion in Huntington disease commenced dosing in September 2005.

The European clinical trial is being conducted in collaboration with Icon and Euro-HD, a non-profit group of physicians and other healthcare professionals dedicated to the research and care of Huntington disease patients.

Rick Stewart, CEO of Amarin, commented; "The commencement of the 240 patient European phase III clinical trial in Huntington's disease is a major milestone for Amarin. The U.S. trial of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2006-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry